Document is current
Any future updates will be listed below
-
Authors
Sarfraz, Zouina https://orcid.org/0000-0002-5132-7455
Ranjan, Tulika
Mustafayev, Fatma Nihan Akkoc
Luzarraga, Joey
Hodgson, Lydia
Ahluwalia, Manmeet S. https://orcid.org/0000-0003-3794-9511
- License Information
-
More Information
Article History
Received: 9 February 2026
Accepted: 11 March 2026
First Online: 8 May 2026
Declarations
:
: An earlier version of this work has been presented previously at the ASCO Annual Meeting 2025: Zouina Sarfraz et al. Site-specific analysis of treatment modalities and survival in brain metastases from neuroendocrine neoplasms: A real-world analysis. J Clin Oncol 43, e14006-e14006(2025). .
: Z.S., T.R., F.N.A.M., J.L.: None. M.S.A.: Has received consulting fees from Bayer, Xoft, Apollomics, Viewray, Cairn Therapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem Therapeutics, GT Medical Technologies, Allovir, EquilliumBio, QV Bioelectronics, Servier Pharmaceuticals, Incyte, Recordati, Genmab, and Novocure. He has served on a Data Safety Monitoring Committee (DSMC) for VBI Vaccines and on the Scientific Advisory Board for Modifibiosciences and Bugworks. M.S.A. is a shareholder in Mimivax, MedInnovate Advisors LLC, and Trisalus Life Sciences.
